Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 CAR-T therapy in autoimmune diseases
NCT06775912Phase 1Recruiting
- Sponsor
- Bioheng Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and 4 more, sponsored by Bioheng Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
RD06-05
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)Neuromyelitis Optica Spectrum Disorder (NMOSD)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06775912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775912.